Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000059.xml
Pneumologie 2023; 77(02): 94-119
DOI: 10.1055/a-1983-6796
DOI: 10.1055/a-1983-6796
Leitlinie
Pharmakotherapie der idiopathischen Lungenfibrose (ein Update) und anderer progredienter pulmonaler Fibrosen
S2k-Leitline der Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin e. V.Pharmacological treatment of idiopathic pulmonary fibrosis (update) and progressive pulmonary fibrosisS2k Guideline of the German Respiratory Society
Schlüsselwörter
idiopathische Lungenfibrose - progrediente pulmonal Fibrose - interstituelle Lungenekrankung - Therapie - Nintedanib - PirfenidonKeywords
idiopatic pulmonary fibrosis - progressive pulmonary fibrosis - interstitial lung disease - therapy - nintedanib - pirfenidonePublication History
Article published online:
15 February 2023
© 2023. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Wijsenbeek M, Cottin V. Spectrum of Fibrotic Lung Diseases. N Engl J Med 2020; DOI: 10.1056/NEJMra2005230.
- 2 Raghu G, Remy-Jardin M, Richeldi L. et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit 2022; DOI: 10.1164/rccm.202202-0399ST.
- 3 Raghu G, Remy-Jardin M, Myers JL. et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit 2018; DOI: 10.1164/rccm.201807-1255ST.
- 4 Behr J, Günther A, Bonella F. et al. S2K Guideline for Diagnosis of Idiopathic Pulmonary Fibrosis. Respiration 2021; DOI: 10.1159/000512315.
- 5 Faverio P, Piluso M, De Giacomi F. et al. Progressive Fibrosing Interstitial Lung Diseases: Prevalence and Characterization in Two Italian Referral Centers. Respiration 2020; DOI: 10.1159/000509556.
- 6 Guler SA, Winstone TA, Murphy D. et al. Does Systemic Sclerosis-associated Interstitial Lung Disease Burn Out? Specific Phenotypes of Disease Progression. Ann Am Thorac Soc 2018; DOI: 10.1513/AnnalsATS.201806-362OC.
- 7 Nasser M, Larrieu S, Si-Mohamed S. et al. Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study). Eur Respir J 2021; DOI: 10.1183/13993003.02718-2020.
- 8 Reiseter S, Molberg Ø, Haydon J. et al. Progression and mortality of interstitial lung disease in mixed connective tissue disease: a long-term observational nationwide cohort study. Rheumatology (Oxford, England) 2018; DOI: 10.1093/rheumatology/kex077.
- 9 Simpson T, Barratt SL, Beirne P. et al. The burden of progressive fibrotic interstitial lung disease across the UK. Eur Respir J 2021; DOI: 10.1183/13993003.00221-2021.
- 10 Zamora-Legoff JA, Krause ML, Crowson CS. et al. Progressive Decline of Lung Function in Rheumatoid Arthritis-Associated Interstitial Lung Disease. Arthritis; rheumatology (Hoboken, N.J.) 2017; DOI: 10.1002/art.39971.
- 11 Flaherty KR, Wells AU, Cottin V. et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. The New England journal of medicine 2019; DOI: 10.1056/NEJMoa1908681.
- 12 Ghazipura M, Mammen MJ, Herman DD. et al. Nintedanib in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Ann Am Thorac Soc 2022; DOI: 10.1513/AnnalsATS.202103-343OC.
- 13 Behr J, Prasse A, Kreuter M. et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med 2021; DOI: 10.1016/S2213-2600(20)30554-3.
- 14 Maher TM, Corte TJ, Fischer A. et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med 2020; DOI: 10.1016/S2213-2600(19)30341-8.
- 15 Cottin V, Hirani NA, Hotchkin DL. et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev 2018; DOI: 10.1183/16000617.0076-2018.
- 16 George PM, Spagnolo P, Kreuter M. et al. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir Med 2019; DOI: 10.1016/S2213-2600(20)30355-6.
- 17 Cottin V. Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases. Eur Respir Rev 2019; DOI: 10.1183/16000617.0109-2019.
- 18 Haidl P, Jany B, Geiseler J. et al. Guideline for Long-Term Oxygen Therapy - S2k-Guideline Published by the German Respiratory Society. Pneumologie (Stuttgart, Germany) 2020; DOI: 10.1055/a-1252-1492.
- 19 Hatabu H, Hunninghake GM, Richeldi L. et al. Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. Lancet Respir Med 2020; DOI: 10.1016/S2213-2600(20)30168-5.
- 20 Behr J, Günther A, Bonella F. et al. German Guideline for Idiopathic Pulmonary Fibrosis – Update on Pharmacological Therapies 2017. Pneumologie (Stuttgart, Germany) 2017; DOI: 10.1055/s-0043-115504.
- 21 Richeldi L, Costabel U, Selman M. et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; DOI: 10.1056/NEJMoa1103690.
- 22 Richeldi L, du Bois RM, Raghu G. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; DOI: 10.1056/NEJMoa1402584.
- 23 Richeldi L, Cottin V, du Bois RM. et al. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials. Respir Med 2016; DOI: 10.1016/j.rmed.2016.02.001.
- 24 Crestani B, Huggins JT, Kaye M. et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir Med 2019; DOI: 10.1016/S2213-2600(18)30339-4.
- 25 Costabel U, Inoue Y, Richeldi L. et al. Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS. Am J Respir Crit 2016; DOI: 10.1164/rccm.201503-0562OC.
- 26 Taniguchi H, Xu Z, Azuma A. et al. Subgroup analysis of Asian patients in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis. Respirology (Carlton, Vic.) 2016; DOI: 10.1111/resp.12852.
- 27 Kolb M, Richeldi L, Behr J. et al. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax 2017; DOI: 10.1136/thoraxjnl-2016-208710.
- 28 Raghu G, Wells AU, Nicholson AG. et al. Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria. Am J Respir Crit 2017; DOI: 10.1164/rccm.201602-0402OC.
- 29 Costabel U, Behr J, Crestani B. et al. Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS® trials. Respir Res 2018; DOI: 10.1186/s12931-018-0866-0.
- 30 Cottin V, Azuma A, Raghu G. et al. Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials. Eur Respir J 2019; DOI: 10.1183/13993003.01655-2018.
- 31 Glaspole I, Bonella F, Bargagli E. et al. Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities. Respir Res 2021; DOI: 10.1186/s12931-021-01695-y.
- 32 Flaherty KR, Kolb M, Vancheri C. et al. Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis. Eur Respir J 2018; DOI: 10.1183/13993003.02593-2017.
- 33 Collard HR, Richeldi L, Kim DS. et al. Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. Eur Respir J 2017; DOI: 10.1183/13993003.01339-2016.
- 34 Kreuter M, Koegler H, Trampisch M. et al. Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials. Respir Res 2019; DOI: 10.1186/s12931-019-1037-7.
- 35 Wuyts WA, Kolb M, Stowasser S. et al. First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50% of Predicted Value. Lung 2016; DOI: 10.1007/s00408-016-9912-1.
- 36 Kolb M, Raghu G, Wells AU. et al. Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med 2018; DOI: 10.1056/NEJMoa1811737.
- 37 Richeldi L, Kolb M, Jouneau S. et al. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulm Med 2020; DOI: 10.1186/s12890-019-1030-4.
- 38 Bonella F, Kreuter M, Hagmeyer L. et al. Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis. Respiration 2016; DOI: 10.1159/000448288.
- 39 Galli JA, Pandya A, Vega-Olivo M. et al. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions. Respirology (Carlton, Vic.) 2017; DOI: 10.1111/resp.13024.
- 40 Brunnemer E, Wälscher J, Tenenbaum S. et al. Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis. Respiration 2018; DOI: 10.1159/000485933.
- 41 Tzouvelekis A, Karampitsakos T, Kontou M. et al. Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: A real-life observational study in Greece. Pulmonary pharmacology therapeutics 2018; DOI: 10.1016/j.pupt.2018.01.006.
- 42 Yoon HY, Park S, Kim DS. et al. Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis. Respir Res 2018; DOI: 10.1186/s12931-018-0907-8.
- 43 Delanote I, Wuyts WA, Yserbyt J. et al. Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series. BMC Pulm Med 2016; DOI: 10.1186/s12890-016-0308-z.
- 44 Leuschner G, Stocker F, Veit T. et al. Outcome of lung transplantation in idiopathic pulmonary fibrosis with previous anti-fibrotic therapy. J Heart Lung Transplant 2017; DOI: 10.1016/j.healun.2017.07.002.
- 45 Lambers C, Boehm PM, Lee S. et al. Effect of antifibrotics on short-term outcome after bilateral lung transplantation: a multicentre analysis. Eur Respir J 2018; DOI: 10.1183/13993003.00503-2018.
- 46 Lancaster L, Crestani B, Hernandez P. et al. Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. BMJ open Respir Res 2018; DOI: 10.1136/bmjresp-2018-000397.
- 47 Guenther A, Krauss E, Tello S. et al. The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis. Respir Res 2018; DOI: 10.1186/s12931-018-0845-5.
- 48 Behr J, Prasse A, Wirtz H. et al. Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. Eur Respir J 2020; DOI: 10.1183/13993003.02279-2019.
- 49 Mooney J, Reddy SR, Chang E. et al. Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis. J Manag Care Spec Pharm 2021; DOI: 10.18553/jmcp.2021.27.12.1724.
- 50 Lasky JA, Criner GJ, Lazarus HM. et al. Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data. Adv Ther 2020; DOI: 10.1007/s12325-020-01452-5.
- 51 Nakazato H, Oku H, Yamane S. et al. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur J Phramacol 2002; DOI: 10.1016/s0014-2999(02)01758-2.
- 52 Kolb M, Bonella F, Wollin L. Therapeutic targets in idiopathic pulmonary fibrosis. Respir Med 2017; DOI: 10.1016/j.rmed.2017.07.062.
- 53 Ghazipura M, Mammen MJ, Bissell BD. et al. Pirfenidone in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Ann Am Thorac Soc 2022; 19: 1030-1039 DOI: 10.1513/AnnalsATS.202103-342OC.
- 54 Raghu G, Johnson WC, Lockhart D. et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit 1999; DOI: 10.1164/ajrccm.159.4.9805017.
- 55 Azuma A, Nukiwa T, Tsuboi E. et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit 2005; DOI: 10.1164/rccm.200404-571OC.
- 56 Taniguchi H, Ebina M, Kondoh Y. et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; DOI: 10.1183/09031936.00005209.
- 57 Noble PW, Albera C, Bradford WZ. et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet (London, England) 2011; DOI: 10.1016/S0140-6736(11)60405-4.
- 58 King Jr TE, Bradford WZ, Castro-Bernardini S. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; DOI: 10.1056/NEJMoa1402582.
- 59 Noble PW, Albera C, Bradford WZ. et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J 2016; DOI: 10.1183/13993003.00026-2015.
- 60 Nathan SD, Albera C, Bradford WZ. et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med 2016; DOI: 10.1016/S2213-2600(16)30326-5.
- 61 Costabel U, Albera C, Lancaster LH. et al. An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP). Respiration 2017; DOI: 10.1159/000479976.
- 62 Lancaster L, Albera C, Bradford WZ. et al. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. BMJ Open Respir Res 2016; DOI: 10.1136/bmjresp-2015-000105.
- 63 Albera C, Costabel U, Fagan EA. et al. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. Eur Respir J 2016; DOI: 10.1183/13993003.01966-2015.
- 64 Nathan SD, Costabel U, Albera C. et al. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment. Respir Med 2019; DOI: 10.1016/j.rmed.2019.04.016.
- 65 Ley B, Swigris J, Day BM. et al. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis. Am J Respir Crit 2017; DOI: 10.1164/rccm.201701-0091OC.
- 66 Nathan SD, Costabel U, Glaspole I. et al. Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis. Chest 2019; DOI: 10.1016/j.chest.2018.11.008.
- 67 Glassberg MK, Wijsenbeek MS, Gilberg F. et al. Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis. Eur Respir J 2019; DOI: 10.1183/13993003.00399-2019.
- 68 Costabel U, Albera C, Glassberg MK. et al. Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis. Respir Res 2019; DOI: 10.1186/s12931-019-1021-2.
- 69 Kreuter M, Lederer DJ, Cottin V. et al. Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis. Eur Respir J 2019; DOI: 10.1183/13993003.01188-2019.
- 70 Cottin V, Koschel D, Günther A. et al. Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study. ERJ open research 2018; DOI: 10.1183/23120541.00084-2018.
- 71 Bonella F, Wessendorf TE, Costabel U. Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis. Dtsch Med Wochenschr 2013; DOI: 10.1055/s-0032-1332930.
- 72 Oltmanns U, Kahn N, Palmowski K. et al. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases. Respiration 2014; DOI: 10.1159/000363064.
- 73 Loeh B, Drakopanagiotakis F, Bandelli GP. et al. Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis. Am J Respir Crit 2015; DOI: 10.1164/rccm.201406-1106LE.
- 74 van Manen MJG, Birring SS, Vancheri C. et al. Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis. Eur Respir J 2017; DOI: 10.1183/13993003.01157-2017.
- 75 Raghu G, Amatto VC, Behr J. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J 2015; DOI: 10.1183/13993003.02316-2014.
- 76 Allaix ME, Fisichella PM, Noth I. et al. The pulmonary side of reflux disease: from heartburn to lung fibrosis. J Gastrointest Surg 2013; DOI: 10.1007/s11605-013-2208-3.
- 77 Raghu G, Pellegrini CA, Yow E. et al. Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial. Lancet Respir Med 2018; DOI: 10.1016/S2213-2600(18)30301-1.
- 78 Tran T, Suissa S. The effect of anti-acid therapy on survival in idiopathic pulmonary fibrosis: a methodological review of observational studies. Eur Respir J 2018; DOI: 10.1183/13993003.00376-2018.
- 79 Kreuter M, Spagnolo P, Wuyts W. et al. Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone. Respiration 2017; DOI: 10.1159/000468546.
- 80 Kreuter M, Wuyts W, Renzoni E. et al. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respir Med 2016; DOI: 10.1016/S2213-2600(16)00067-9.
- 81 Tran T, Suissa S. Comparing New-User Cohort Designs: The Example of Proton Pump Inhibitor Effectiveness in Idiopathic Pulmonary Fibrosis. Am J Epidemiol 2021; DOI: 10.1093/aje/kwaa242.
- 82 Tran T, Assayag D, Ernst P. et al. Effectiveness of Proton Pump Inhibitors in Idiopathic Pulmonary Fibrosis: A Population-Based Cohort Study. Chest 2021; DOI: 10.1016/j.chest.2020.08.2080.
- 83 Demedts M, Behr J, Buhl R. et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; DOI: 10.1056/NEJMoa042976.
- 84 Martinez FJ, de Andrade JA, Anstrom KJ. et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2014; DOI: 10.1056/NEJMoa1401739.
- 85 Feng F, Zhang J, Wang Z. et al. Efficacy and safety of N-acetylcysteine therapy for idiopathic pulmonary fibrosis: An updated systematic review and meta-analysis. Exp Ther Med 2019; DOI: 10.3892/etm.2019.7579.
- 86 Behr J, Bendstrup E, Crestani B. et al. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med 2016; DOI: 10.1016/S2213-2600(16)30044-3.
- 87 Shi H, Yin D, Bonella F. et al. Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis. BMC Pulm Med 2020; DOI: 10.1186/s12890-020-1121-2.
- 88 Sakamoto S, Kataoka K, Kondoh Y. et al. Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial. Eur Respir J 2021; DOI: 10.1183/13993003.00348-2020.
- 89 Oldham JM, Ma SF, Martinez FJ. et al. TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. Am J Respir Crit 2015; DOI: 10.1164/rccm.201505-1010OC.
- 90 Oldham JM, Witt LJ, Adegunsoye A. et al. N-acetylcysteine exposure is associated with improved survival in anti-nuclear antibody seropositive patients with usual interstitial pneumonia. BMC Pulm Med 2018; DOI: 10.1186/s12890-018-0599-3.
- 91 Raja SG. Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis. Curr Opin Investig Drugs 2010; 11: 1066-1073
- 92 King Jr TE. Bosentan for idiopathic pulmonary fibrosis. Curr Opin Investig Drugs 2008; 9: 1171-1179
- 93 King Jr TE, Behr J, Brown KK. et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit 2008; DOI: 10.1164/rccm.200705-732OC.
- 94 King Jr TE, Brown KK, Raghu G. et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit 2001; DOI: 10.1164/rccm.201011-1874OC.
- 95 Raghu G, Million-Rousseau R, Morganti A. et al. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Respir J 2013; DOI: 10.1183/09031936.00104612.
- 96 Corte TJ, Keir GJ, Dimopoulos K. et al. Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Am J Respir Crit 2014; DOI: 10.1164/rccm.201403-0446OC.
- 97 Zisman DA, Schwarz M, Anstrom KJ. et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010; DOI: 10.1056/NEJMoa1002110.
- 98 Jackson RM, Glassberg MK, Ramos CF. et al. Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis. Lung 2010; DOI: 10.1007/s00408-009-9209-8.
- 99 Han MK, Bach DS, Hagan PG. et al. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest 2013; DOI: 10.1378/chest.12-1594.
- 100 Behr J, Nathan SD, Wuyts WA. et al. Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med 2021; DOI: 10.1016/S2213-2600(20)30356-8.
- 101 Behr J, Nathan SD, Harari S. et al. Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design. Respir Med 2018; DOI: 10.1016/j.rmed.2018.03.019.
- 102 Behr J, Kolb M, Song JW. et al. Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE). Am J Respir Crit 2019; DOI: 10.1164/rccm.201903-0488OC.
- 103 Cottin V, Richeldi L, Rosas I. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases. Respir Res 2021; DOI: 10.1186/s12931-021-01668-1.
- 104 Yamagata A, Arita M, Tachibana H. et al. Impact of bronchoalveolar lavage lymphocytosis on the effects of anti-inflammatory therapy in idiopathic non-specific interstitial pneumonia, idiopathic pleuroparenchymal fibroelastosis, and unclassifiable idiopathic interstitial pneumonia. Respir Res 2021; DOI: 10.1186/s12931-021-01726-8.
- 105 Wijsenbeek M, Kreuter M, Olson A. et al. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Curr Med Res Opin 2019; DOI: 10.1080/03007995.2019.1647040.
- 106 Takizawa A, Kamita M, Kondoh Y. et al. Current monitoring and treatment of progressive fibrosing interstitial lung disease: a survey of physicians in Japan, the United States, and the European Union. Curr Med Res Opin 2021; DOI: 10.1080/03007995.2020.1860920.
- 107 Teoh AKY, Corte TJ. Nonspecific Interstitial Pneumonia. Semin Respir Crit Care Med 2020; DOI: 10.1055/s-0040-1708499.
- 108 Lee JY, Jin SM, Lee BJ. et al. Treatment response and long term follow-up results of nonspecific interstitial pneumonia. J Korean Med Sci 2012; DOI: 10.3346/jkms.2012.27.6.661.
- 109 Nanki N, Fujita J, Yamaji Y. et al. Nonspecific interstitial pneumonia/fibrosis completely recovered by adding cyclophosphamide to corticosteroids. Intern Med (Tokyo, Japan) 2002; DOI: 10.2169/internalmedicine.41.867.
- 110 Corte TJ, Ellis R, Renzoni EA. et al. Use of intravenous cyclophosphamide in known or suspected, advanced non-specific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26: 132-138
- 111 Kondoh Y, Taniguchi H, Yokoi T. et al. Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia. Eur Respir J 2005; DOI: 10.1183/09031936.05.00071004.
- 112 Morisset J, Johannson KA, Vittinghoff E. et al. Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity Pneumonitis. Chest 2017; DOI: 10.1016/j.chest.2016.10.029.
- 113 Adegunsoye A, Oldham JM, Fernández Pérez ER. et al. Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis. ERJ open research 2017; DOI: 10.1183/23120541.00016-2017.
- 114 Ferreira M, Borie R, Crestani B. et al. Efficacy and safety of rituximab in patients with chronic hypersensitivity pneumonitis (cHP): A retrospective, multicentric, observational study. Respir Med 2020; DOI: 10.1016/j.rmed.2020.106146.
- 115 Fernández Pérez ER, Swigris JJ, Forssén AV. et al. Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis. Chest 2013; DOI: 10.1378/chest.12-2685.
- 116 Raghu G, Remy-Jardin M, Ryerson CJ. et al. Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit 2020; DOI: 10.1164/rccm.202005-2032ST.
- 117 De Sadeleer LJ, Hermans F, De Dycker E. et al. Effects of Corticosteroid Treatment and Antigen Avoidance in a Large Hypersensitivity Pneumonitis Cohort: A Single-Centre Cohort Study. J Clin Med 2018; DOI: 10.3390/jcm8010014.
- 118 Juge PA, Solomon JJ, van Moorsel CHM. et al. MUC5B promoter variant rs35705950 and rheumatoid arthritis associated interstitial lung disease survival and progression. Semin Arthritis Rheum 2021; DOI: 10.1016/j.semarthrit.2021.07.002.
- 119 Juge PA, Lee JS, Ebstein E. et al. MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. N Engl J Med 2018; DOI: 10.1056/NEJMoa1801562.
- 120 Kiely P, Busby AD, Nikiphorou E. et al. Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. BMJ open 2019; DOI: 10.1136/bmjopen-2018-028466.
- 121 Conway R, Low C, Coughlan RJ. et al. Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials. BMJ (Clinical research ed.) 2015; DOI: 10.1136/bmj.h1269.
- 122 Huang S, Kronzer VL, Dellaripa PF. et al. Rheumatoid arthritis-associated interstitial lung disease: Current update on prevalence, risk factors, and pharmacologic treatment. Curr Treatm Opt Rheumatol 2020; DOI: 10.1007/s40674-020-00160-z.
- 123 Seeliger B, Prasse A. Immunomodulation in Autoimmune Interstitial Lung Disease. Respiration 2020; DOI: 10.1159/000511200.
- 124 Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum 2014; DOI: 10.1016/j.semarthrit.2013.09.005.
- 125 Druce KL, Iqbal K, Watson KD. et al. Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic. RMD open 2017; DOI: 10.1136/rmdopen-2017-000473.
- 126 Lee CT, Strek ME. The other connective tissue disease-associated interstitial lung diseases: Sjogrenʼs syndrome, mixed connective tissue disease, and systemic lupus erythematosus. Curr Opin Pulm Med 2021; DOI: 10.1097/MCP.0000000000000791.
- 127 Parambil JG, Myers JL, Lindell RM. et al. Interstitial lung disease in primary Sjögren syndrome. Chest 2006; DOI: 10.1378/chest.130.5.1489.
- 128 Fujisawa T, Hozumi H, Kono M. et al. Prognostic factors for myositis-associated interstitial lung disease. PloS one 2014; DOI: 10.1371/journal.pone.0098824.
- 129 Wu W, Guo L, Fu Y. et al. Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis. Clin Rev Allergy Immunol 2021; DOI: 10.1007/s12016-020-08822-5.
- 130 Yamasaki Y, Yamada H, Yamasaki M. et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford, England) 2007; DOI: 10.1093/rheumatology/kel112.
- 131 Huapaya JA, Silhan L, Pinal-Fernandez I. et al. Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease. Chest 2019; DOI: 10.1016/j.chest.2019.05.023.
- 132 Takada K, Katada Y, Ito S. et al. Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis/dermatomyositis: a single-arm clinical trial. Rheumatology (Oxford, England) 2020; DOI: 10.1093/rheumatology/kez394.
- 133 Fujisawa T, Hozumi H, Kamiya Y. et al. Prednisolone and tacrolimus vs. prednisolone and cyclosporin A to treat polymyositis/dermatomyositis-associated ILD: A randomized, open-label trial. Respirology (Carlton, Vic.) 2021; DOI: 10.1111/resp.13978.
- 134 Tsuji H, Nakashima R, Hosono Y. et al. Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis. Arthritis Rheumatol (Hoboken, N.J.) 2020; DOI: 10.1002/art.41105.
- 135 Chen Z, Wang X, Ye S. Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease. N Engl J Med 2019; DOI: 10.1056/NEJMc1900045.
- 136 He C, Li W, Xie Q. et al. Rituximab in the Treatment of Interstitial Lung Diseases Related to Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis: A Systematic Review. Front Immunol 2021; DOI: 10.3389/fimmu.2021.820163.
- 137 Allenbach Y, Guiguet M, Rigolet A. et al. Efficacy of Rituximab in Refractory Inflammatory Myopathies Associated with Anti- Synthetase Auto-Antibodies: An Open-Label, Phase II Trial. PloS one 2015; DOI: 10.1371/journal.pone.0133702.
- 138 Ebata S, Yoshizaki A, Fukasawa T. et al. Percentage of residual B cells after 2 weeks of rituximab treatment predicts the improvement of systemic sclerosis-associated interstitial lung disease. J Dermatol 2022; DOI: 10.1111/1346-8138.16206.
- 139 Tashkin DP, Elashoff R, Clements PJ. et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007; 176: 1026-1034 DOI: 10.1164/rccm.200702-326OC.
- 140 Hoyles RK, Ellis RW, Wellsbury J. et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; DOI: 10.1002/art.22204.
- 141 Tashkin DP, Elashoff R, Clements PJ. et al. Cyclophosphamide vs. placebo in scleroderma lung disease. N Engl J Med 2006; DOI: 10.1056/NEJMoa055120.
- 142 Tashkin DP, Roth MD, Clements PJ. et al. Mycophenolate mofetil vs. oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016; DOI: 10.1016/S2213-2600(16)30152-7.
- 143 Highland KB, Distler O, Kuwana M. et al. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respir Med 2021; DOI: 10.1016/S2213-2600(20)30330-1.
- 144 Khanna D, Denton CP, Lin CJF. et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis 2018; DOI: 10.1136/annrheumdis-2017-211682.
- 145 Khanna D, Lin CJF, Furst DE. et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 2020; DOI: 10.1016/S2213-2600(20)30318-0.
- 146 Ebata S, Yoshizaki A, Oba K. et al. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol 2021; DOI: 10.1016/S2665-9913(22)00131-X.
- 147 Sircar G, Goswami RP, Sircar D. et al. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology (Oxford, England) 2018; DOI: 10.1093/rheumatology/key213.
- 148 Burt RK, Shah SJ, Dill K. et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet (London, England) 2011; DOI: 10.1016/S0140-6736(11)60982-3.
- 149 van Laar JM, Nihtyanova SI, Naraghi K. et al. Autologous HSCT for systemic sclerosis. Lancet (London, England) 2013; DOI: 10.1016/S0140-6736(13)61239-8.
- 150 Sullivan KM, Goldmuntz EA, Keyes-Elstein L. et al. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med 2018; DOI: 10.1056/nejmoa1703327.
- 151 Henes J, Oliveira MC, Labopin M. et al. Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party. Haematologica 2021; DOI: 10.3324/haematol.2019.230128.
- 152 Finnerty JP, Ponnuswamy A, Dutta P. et al. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. BMC Pulm Med 2021; DOI: 10.1186/s12890-021-01783-1.
- 153 Nasser M, Si-Mohamed S, Turquier S. et al. Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis. Orphanet J Rare Dis 2021; DOI: 10.1186/s13023-021-02043-5.
- 154 Inoue Y, Suda T, Kitamura H. et al. Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial. Respir Med 2021; DOI: 10.1016/j.rmed.2021.106574.
- 155 Flaherty KR, Wells AU, Cottin V. et al. Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. Eur Respir J 2022; DOI: 10.1183/13993003.04538-2020.
- 156 Maher TM, Brown KK, Kreuter M. et al. Effects of nintedanib by inclusion criteria for progression of interstitial lung disease. Eur Respir J 2022; DOI: 10.1183/13993003.04587-2020.
- 157 Behr J, Günther A, Bonella F. et al. German Guideline for Idiopathic Pulmonary Fibrosis – Update on Pharmacological Therapies 2017. Pneumologie (Stuttgart, Germany) 2018; DOI: 10.1055/s-0043-123035.
- 158 Wells AU, Flaherty KR, Brown KK. et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med 2020; DOI: 10.1016/S2213-2600(20)30036-9.
- 159 Solomon JJ, Danoff SK, Goldberg HJ. et al. The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease. Adv Ther 2019; DOI: 10.1007/s12325-019-01086-2 .
- 160 Lettieri CJ, Nathan SD, Barnett SD. et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; DOI: 10.1378/chest.129.3.746.
- 161 King Jr TE, Tooze JA, Schwarz MI. et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit 2001; DOI: 10.1164/ajrccm.164.7.2003140.
- 162 Olschewski H, Ghofrani HA, Walmrath D. et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit 1999; DOI: 10.1164/ajrccm.160.2.9810008.
- 163 Waxman A, Restrepo-Jaramillo R, Thenappan T. et al. Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. N Engl J Med 2021; DOI: 10.1056/NEJMoa2008470.
- 164 Swigris JJ, Wamboldt FS, Behr J. et al. The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax 2010; DOI: 10.1136/thx.2009.113498.
- 165 Rose F, Zwick K, Ghofrani HA. et al. Prostacyclin enhances stretch-induced surfactant secretion in alveolar epithelial type II cells. Am J Respir Crit 1999; DOI: 10.1164/ajrccm.160.3.9812155.
- 166 Bauman KA, Wettlaufer SH, Okunishi K. et al. The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice. J Clin Invest 2010; DOI: 10.1172/JCI38369.
- 167 Lama V, Moore BB, Christensen P. et al. Prostaglandin E2 synthesis and suppression of fibroblast proliferation by alveolar epithelial cells is cyclooxygenase-2-dependent. Am J Respir Cell Mol Biol 2002; DOI: 10.1165/rcmb.4857.
- 168 Maher TM, Stowasser S, Nishioka Y. et al. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. Lancet Respir Med 2019; DOI: 10.1016/S2213-2600(19)30255-3.
- 169 Taguchi Y, Ebina M, Hashimoto S. et al. Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan. Respir Investig 2015; DOI: 10.1016/j.resinv.2015.06.002.
- 170 Wells AU, Brown KK, Cottin V. The progressive fibrotic phenotype in current clinical practice. Curr Opin Pulm Med 2021; DOI: 10.1097/MCP.0000000000000805.
- 171 Adegunsoye A, Oldham JM, Bellam SK. et al. Computed Tomography Honeycombing Identifies a Progressive Fibrotic Phenotype with Increased Mortality across Diverse Interstitial Lung Diseases. Ann Am Thorac Soc 2019; DOI: 10.1513/AnnalsATS.201807-443OC.
- 172 Salisbury ML, Gu T, Murray S. et al. Hypersensitivity Pneumonitis: Radiologic Phenotypes Are Associated With Distinct Survival Time and Pulmonary Function Trajectory. Chest 2019; DOI: 10.1016/j.chest.2018.08.1076.
- 173 Richeldi L, Kreuter M, Selman M. et al. Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension. Thorax 2018; DOI: 10.1136/thoraxjnl-2016-209701.
- 174 Suzuki Y, Mori K, Aono Y. et al. Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study. BMC Pulm Med 2021; DOI: 10.1186/s12890-021-01587-3.
- 175 Vianello A, Salton F, Molena B. et al. Nintedanib Treatment for Idiopathic Pulmonary Fibrosis Patients Who Have Been Switched from Pirfenidone Therapy: A Retrospective Case Series Study. J Clin Med 2020; DOI: 10.3390/jcm9020422.
- 176 Milger K, Kneidinger N, Neurohr C. et al. Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF. Eur Respir J 2015; DOI: 10.1183/13993003.00584-2015.
- 177 Adams CJ, Shapera S, Ryerson CJ. et al. Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study. Respir Med 2022; DOI: 10.1016/j.rmed.2021.106722.
- 178 Nathan SD, Albera C, Bradford WZ. et al. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax 2016; DOI: 10.1136/thoraxjnl-2015-207011.
- 179 Richeldi L, Crestani B, Azuma A. et al. Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON trials of nintedanib. Respir Med 2019; DOI: 10.1016/j.rmed.2019.08.002.
- 180 Behr J, Günther A, Kreuter M. et al. Expert Knowledge and Supporting Advice for the Clinical Use of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis. Pneumologie (Stuttgart, Germany) 2017; DOI: 10.1055/s-0043-109856.
- 181 Lancaster LH, de Andrade JA, Zibrak JD. et al. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. Eur Respir Rev 2017; DOI: 10.1183/16000617.0057-2017.
- 182 Costabel U, Bendstrup E, Cottin V. et al. Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Adv Ther 2014; DOI: 10.1007/s12325-014-0112-1.
- 183 Wuyts WA, Antoniou KM, Borensztajn K. et al. Combination therapy: the future of management for idiopathic pulmonary fibrosis?. Lancet Respir Med 2014; DOI: 10.1016/S2213-2600(14)70232-2.
- 184 Ogura T, Taniguchi H, Azuma A. et al. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2015; DOI: 10.1183/09031936.00198013.
- 185 Vancheri C, Kreuter M, Richeldi L. et al. Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. Am J Respir Crit 2018; DOI: 10.1164/rccm.201706-1301OC.
- 186 Flaherty KR, Fell CD, Huggins JT. et al. Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis. Eur Respir J 2018; DOI: 10.1183/13993003.00230-2018.
- 187 Hisata S, Bando M, Homma S. et al. Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan. Respiratory investigation 2021; DOI: 10.1016/j.resinv.2021.04.005.
- 188 du Bois RM, Weycker D, Albera C. et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit 2011; DOI: 10.1164/rccm.201105-0840OC.
- 189 Chung MP, Park MS, Oh IJ. et al. Safety and Efficacy of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis: A Nationwide Post-Marketing Surveillance Study in Korean Patients. Adv Ther 2020; DOI: 10.1007/s12325-020-01328-8.
- 190 Yoon HY, Kim DS, Song JW. Efficacy and Safety of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis. Respiration 2019; DOI: 10.1159/000492937.
- 191 Raghu G, Anstrom KJ, King Jr TE. et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; DOI: 10.1056/NEJMoa1113354.
- 192 Blanc PD, Annesi-Maesano I, Balmes JR. et al. The Occupational Burden of Nonmalignant Respiratory Diseases. An Official American Thoracic Society and European Respiratory Society Statement. Am J Respir Crit Care Med 2019; 199: 1312-1334 DOI: 10.1164/rccm.201904-0717ST.
- 193 Park Y, Ahn C, Kim TH. Occupational and environmental risk factors of idiopathic pulmonary fibrosis: a systematic review and meta-analyses. Sci Rep 2021; 11: 4318 DOI: 10.1038/s41598-021-81591-z.
- 194 Abramson MJ, Murambadoro T, Alif SM. et al. Australian IPF Registry. Occupational and environmental risk factors for idiopathic pulmonary fibrosis in Australia: case-control study. Thorax 2020; 75: 864-869 DOI: 10.1136/thoraxjnl-2019-214478.
- 195 Miedema JR, Moor CC, Veltkamp M. et al. Safety and tolerability of pirfenidone in asbestosis: a prospective multicenter study. Respir Res 2022; 23: 139 DOI: 10.1186/s12931-022-02061-2.
- 196 Bonella F, Cottin V, Valenzuela C. et al. Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases. Adv Ther 2022; 39: 3392-3402 DOI: 10.1007/s12325-022-02145-x.
- 197 Zeng Y, Jiang Y, Banks DE. The Effectiveness of Whole Lung Lavage in Pneumoconiosis: A Systematic Review and Meta-Analysis. J Occup Environ Med 2022; 64: e492-e499 DOI: 10.1097/JOM.0000000000002599.
- 198 Newton CA, Zhang D, Oldham JM. et al. Telomere Length and Use of Immunosuppressive Medications in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2019; 200: 336-347 DOI: 10.1164/rccm.201809-1646OC.